NeoGenomics, Inc.

NASDAQ:NEO

Medical - Diagnostics & Research

Healthcare
$15.29 +6.03%

+$0.63 today

Market cap
$1.99B
Beta
1.81
P/E (TTM)
-2.9
EPS (TTM)
-$3.84
52W Low $4.72High $13.74

Volume 1.09M

Average 1.94M

NEO EBITDA Margin

EBITDA as a percentage of revenue.

NeoGenomics, Inc.NASDAQ: NEO

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 9.3%

EBITDA Margin was 9.3% in Q2 FY2026, up 24.6 pp from a year earlier. On a trailing-twelve-month basis it was 1.7%, up 5.8 pp year over year. Over 3 fiscal years it widened by 10.8 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 8 analysts of 12.5% for the fiscal year ending Dec 2026, up from -5.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
9.3%+9.6 pp QoQ
Last fiscal yearDec 2025
-5.3%-5.1 pp YoY
LTMJun 2026
1.7%+5.8 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+24.6 pp+17.7 pp-6.8 pp
1 year-5.1 pp+17.9 pp+22.9 pp
3 years+10.8 pp+19.2 pp+8.4 pp
5 years+22.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-5.3%
Year-over-year change
-5.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NEO compares with its peers on the latest reported figures

  • NEO's LTM Jun 2026 EBITDA Margin of 1.7% is the 2nd highest of the 10 companies compared; the peer median is -19.1%.
  • Its year-over-year change of +5.8 pp is the 4th highest of 10, against a peer median of +1.5 pp.
  • Over three fiscal years its change of +10.8 pp compares with a peer median of +87.2 pp.
NEO Competitors Peer median
EBITDA Margin for NEO and competitors
Company Period LTM level YoY 3-year change
VCYTVeracyte, Inc.LTM Jun 202623.1% +13.6 pp+20.8 pp
NEONeoGenomics, Inc.LTM Jun 20261.7% +5.8 pp+10.8 pp
CSTLCastle Biosciences, Inc.LTM Mar 2026-0.2% -12.0 pp+45.9 pp
WGSGeneDx Holdings Corp.LTM Jun 2026-16.8% -24.5 pp+171.2 pp
XGNExagen Inc.LTM Mar 2026-18.9% +1.5 pp+75.6 pp
BDSXBiodesix, Inc.LTM Mar 2026-19.1% +17.8 pp+110.1 pp
GHGuardant Health, Inc.LTM Sep 2026-34.5% +4.7 pp+98.7 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-40.3% -32.6 pp-27.6 pp
PSNLPersonalis, Inc.LTM Mar 2026-132.6% -47.0 pp—
GRALGRAIL, Inc.LTM Jun 2026-226.4% +86.1 pp+801.0 pp
FRNMFreenome, Inc. Common stock—— ——
Peer median (excluding NEO) -19.1%+1.5 pp+87.2 pp

Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue484.33M509.73M591.64M660.57M727.33M
Cost of Revenue297.27M321.83M347.04M370.47M444.79M
Gross Profit187.06M187.9M244.6M290.1M282.54M
Gross Margin38.6%36.9%41.3%43.9%38.8%
Research & Development21.87M30.33M27.31M31.16M37.08M
Selling, General & Admin283.94M277.91M279.96M310.49M365.34M
Operating Expenses305.81M345.52M352.34M382.21M348.62M
Depreciation & Amortization53.35M69.43M72.58M72.55M67.82M
EBITDA46.5M(82.33M)(17.61M)(1.51M)(38.69M)
EBITDA Margin9.6%-16.2%-3.0%-0.2%-5.3%
Operating Income(118.75M)(157.62M)(107.74M)(92.11M)(66.08M)
Operating Margin-24.5%-30.9%-18.2%-13.9%-9.1%
Interest Income3.14M6.08M16.9M18.43M9.07M
Interest Expense8.22M7.58M6.91M6.62M3.75M
Other Income / Expenses103.68M(1.72M)10.64M11.43M(44.19M)
Income Before Tax(15.08M)(159.34M)(97.1M)(80.68M)(110.27M)
Pre-Tax Margin-3.1%-31.3%-16.4%-12.2%-15.2%
Income Tax Expense(6.73M)(15.09M)(9.13M)(1.95M)(2.24M)
Net Income(8.35M)(144.25M)(87.97M)(78.73M)(108.03M)
Net Margin-1.7%-28.3%-14.9%-11.9%-14.9%
EPS (Basic)(0.07)(1.16)(0.70)(0.62)(0.84)
EPS (Diluted)(0.07)(1.16)(0.70)(0.62)(0.84)
Weighted Avg Shares119.96M124.22M125.5M126.66M128.1M
Weighted Avg Shares (Diluted)119.96M124.22M125.5M126.66M128.1M

NeoGenomics, Inc.

NASDAQ:NEO

Intrinsic Alpha fair value

Locked

Current Price

$15.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.